 |
| Attached files |
| File | Filename |
|---|
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R15.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R7.htm |
| 10-Q - Q Therapeutics, Inc. | form10q.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R20.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R10.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R5.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R21.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R16.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R14.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R19.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R23.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R11.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R12.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R4.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R18.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R1.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R17.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R3.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R24.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R22.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R6.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R2.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R8.htm |
| EXCEL - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | Financial_Report.xls |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R9.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R25.htm |
| EX-32.2 - Q Therapeutics, Inc. | ex32-2.htm |
| EX-32.1 - Q Therapeutics, Inc. | ex32-1.htm |
| EX-31.2 - Q Therapeutics, Inc. | ex31-2.htm |
| EX-31.1 - Q Therapeutics, Inc. | ex31-1.htm |
| EX-14.1 - Q Therapeutics, Inc. | ex14-1.htm |
| EX-3.2 - Q Therapeutics, Inc. | ex3-2.htm |
| EX-3.1 - Q Therapeutics, Inc. | ex3-1.htm |
v2.4.0.6
|
Subsequent Events
|
9 Months Ended |
|
Sep. 30, 2012
|
| Subsequent Events [Abstract] |
|
| Subsequent Events |
| 6. |
Subsequent Events |
|
On October 1, 2012 the Company entered into a services agreement with a public relations and investor relations firm. Under the agreement, the Company will issue 50,000 shares of common stock in lieu of cash for services to be rendered over the next five months. Upon expiration of the initial term, a monthly cash retainer of up to $10,000 will be incurred. Additionally, up to 250,000 warrants may be issued with exercise prices varying between $1.25 and $2.75 over the next twelve months upon the achievement of time based objectives. |
| |
|
|
|
| |
|
|
On October 9, 2012, the Company filed with the Secretary of State of the State of Delaware an Amendment to the Certificate of Incorporation of Q Therapeutics, Inc. therein changing the name of Q Therapeutics, Inc. to Q Therapeutic Products, Inc., effective immediately. |
| |
|
|
|
| |
|
|
On October 16, 2012, the Company entered into an agreement with a financial advisor and placement agent in connections with possible capital raising transactions. Under the agreement, the financial advisor will receive a 7% commission on offering proceeds and five year warrants to purchase common stock valued at 10% of the common stock sold. The agreement is expected to continue for a period of at least six months. |
| |
|
|
|
| |
|
|
On October 30, 2012, the Company filed with the Secretary of State of the State of Delaware an Amendment to the Certificate of Incorporation of Q Holdings, Inc. therein changing the name of Q Holdings, Inc. to Q Therapeutics, Inc., effective December 10, 2012. |
|
| X |
- Details
| Name: |
us-gaap_SubsequentEventsAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References+ Details
| Name: |
us-gaap_SubsequentEventsTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
This web site and associated pages are not associated with, endorsed by, or sponsored by Q Therapeutics, Inc. and has no official or unofficial affiliation with Q Therapeutics, Inc.
Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site. Use at your own risk.
This website is not associated with the SEC
Some parts © 2013 Advameg, Inc.
|
|
